



Alexei F Kisselev

Kontakt

Alexei F Kisselev

Publikationen (8)

Xin B, Groll M, van der Marel G, Driessen C, Florea B, Kisselev A, Weyburne E, Janssens M, Du Y, Espinal C, Maurits E, Heinemeyer W, de Bruin G, Huber E, Overkleeft H. Structure-Based Design of Inhibitors Selective for Human Proteasome β 2c or β 2i Subunits. *J Med Chem* 2019; 62:1626–1642.

Downey-Kopyscinski S, Overkleeft H, Driessen C, Richardson P, Mitsiades C, Florea B, Bhatt A, Gautier M, Daily E, Kisselev A. An inhibitor of proteasome β 2 sites sensitizes myeloma cells to immunoproteasome inhibitors. *Blood Adv* 2018; 2:2443–2451.

Xin B, Groll M, Driessen C, van der Stelt M, Kisselev A, van der Marel G, Filippov D, Florea B, Besse A, Huber E, de Bruin G, Overkleeft H. Structure-Based Design of β 5c Selective Inhibitors of Human Constitutive Proteasomes. *J Med Chem* 2016; 59:7177–87.

de Bruin G, Xin B, Kraus M, van der Stelt M, van der Marel G, Kisselev A, Driessen C, Florea B, Overkleeft H. A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities. *Angew Chem Int Ed Engl* 2015; 55:4199–203.

Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink P, de Bruin G, Kisselev A, Overkleeft H, Driessen C. The novel β 2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. *Cancer Chemother Pharmacol* 2015; 76:383–96.

Kraus M, Overkleeft H, Kisselev A, Li N, Appenzeller C, van Rooden E, Haile S, de Bruin G, van der Linden W, Shabaneh T, Silzle T, Mirabella A, Weyburne E, Geurink P, Bader J, Driessen C. The novel β 2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. *Haematologica* 2015; 100:1350–60.

de Bruin G, Groll M, van der Marel G, van der Stelt M, Driessen C, Kisselev A, Kim K, Al-Ayed K, van Rooden E, Xin B, Huber E, Overkleeft H. Structure-based design of β 1i or β 5i specific inhibitors of human immunoproteasomes. *J Med Chem* 2014; 57:6197–209.

Geurink P, Overkleeft H, Groll M, van der Stelt M, Driessen C, van der Marel G, Florea B, Mock E, Voges M, Blom A, de Bruin G, Gallastegui N, Mirabella A, van der Linden W, Kisselev A. Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites. *J Med Chem* 2013; 56:1262–75.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch